Fermion Oy Fermion Oy

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Cu-67 SAR-Bombesin in Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for 64Cu-SAR-BBN

    Menu

    64Cu-SAR-BBN

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Clarity Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Treated with Cu-67 SAR-Bombesin in Theranostic Prostate Cancer Trial

              Details:

              SAR-Bombesin is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).

              Lead Product(s): 64Cu-SAR-BBN

              Therapeutic Area: Oncology Product Name: SAR-Bombesin

              Highest Development Status: Phase I/ Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.
              Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.
              Post Enquiry
              POST ENQUIRY